Recent Comments

Comment RSS

Search results for 'Anti-angiogenesis '


Press conference highlights emerging treatments in pancreatic cancer As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET. http://www.news-medical.net/news/20091118/Press-conference-highlights-emerging-treatments-in-pancreatic-cancer.aspx
Thalidomide does not improve survival in small cell lung cancer Treating patients with thalidomide in combination with chemotherapy for small cell lung cancer (SCLC) did not improve their survival but did increase their risk of blood clots, according to a new study published online July 16 in the Journal of the National Cancer Institute. http://www.news-medical.net/news/20090717/Thalidomide-does-not-improve-survival-in-small-cell-lung-cancer.aspx
Paradox of cancer drugs gives clue to why some treatments fail Cancer Research UK funded scientists have found that some types of cancer drugs called angiogenesis inhibitors can encourage tumour growth rather than stunt it - according to research published in Nature Medicine. http://www.news-medical.net/news/2009/03/22/47150.aspx
Angiogenesis inhibitors, study points to limitations, solutions A new generation of cancer drugs designed to starve tumors of their blood supply - called "angiogenesis inhibitors"-succeeds at first, but then promotes more invasive cancer growth-sometimes with a higher incidence of metastases, according to a new study in animals. http://www.news-medical.net/news/2009/03/02/46387.aspx
Further evidence that angiogenesis drugs can be much more effective when combined with chemotherapy Scientists have thought that one way to foil a tumor from generating blood vessels to feed its growth - a process called angiogenesis - was by creating drugs aimed at stopping a key vessel growth-promoting protein. http://www.news-medical.net/news/2008/11/10/42637.aspx
Peregrine licenses worldwide rights to a novel anti-angiogenesis technology Peregrine Pharmaceuticals, Inc. has announced that it has licensed worldwide exclusive rights to a novel anti-angiogenesis technology from The University of Texas M. D. Anderson Cancer Center. http://www.news-medical.net/news/2007/07/10/27372.aspx
Lexicon Reports on anti-angiogenesis target discoveries Lexicon Genetics has presented results from the company's genetic screen to identify proteins involved in blood vessel formation and organization. http://www.news-medical.net/news/2007/04/18/23778.aspx
Researchers identify how molecules of microRNA are responsible for the growth of blood vessels in a model for human colon cancer The process, called angiogenesis, results in ability of ravenous cancer cells to recruit blood vessels and receive a steady supply of nutrients and oxygen. http://www.news-medical.net/news/2006/08/04/19279.aspx
Avastin trial for pancreatic tumors "Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti. http://www.news-medical.net/news/2006/02/23/16148.aspx
M. D. Anderson Cancer Center to investigate CTCE-9908 chemokine CXCR4 antagonist Chemokine Therapeutics has announced that it has entered into an agreement with The University of Texas M. D. Anderson Cancer Center of Houston, Texas to study the Company's lead anti-cancer compound, CTCE-9908, a chemokine CXCR4 antagonist. http://www.news-medical.net/news/2006/02/21/16120.aspx
Amazing 'smart bomb' drug zaps cancer cells in mice without damaging healthy cells Scientists say they have developed an anti-cancer 'bomb' which has a similar behavior to a Trojan horse. http://www.news-medical.net/news/2005/07/28/12108.aspx
Cancer biology, pharmacology and engineering combine to create cancer smart bomb Imagine a cancer drug that can burrow into a tumor, seal the exits and detonate a lethal dose of anti-cancer toxins, all while leaving healthy cells unscathed. http://www.news-medical.net/news/2005/07/27/12069.aspx
Cancer cells may be able to avoid destruction by anti-vascular and anti-angiogenesis agents Cancer cells may be able to avoid destruction by anti-vascular and anti-angiogenesis agents through a cellular stress response that activates a pro-survival protein called GRP78, according to researchers from the Keck School of Medicine of the University of Southern California. http://www.news-medical.net/news/2005/07/06/11515.aspx
Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer A targeted cancer drug given with low-dose chemotherapy shrank ovarian tumors and slowed progression of ovarian cancer in patients with recurrent disease, according to research findings presented by Agustin Garcia, M.D., principal investigator of the study and Director of Breast Cancer Research at the Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. http://www.news-medical.net/news/2005/05/16/10079.aspx
Counting number of endothelial cells in blood may predict cancer treatment's effectiveness Counting the amount of a type of normal cell circulating in the blood of people with cancer could predict whether a tumor progresses or responds to therapy, a new study led by the University of Michigan Comprehensive Cancer Center has found. The finding could give doctors an early indication of whether a treatment will be successful, sparing patients months of an ineffective therapy. http://www.news-medical.net/news/2005/05/15/10014.aspx
Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS) Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. http://www.news-medical.net/news/2005/02/10/7707.aspx
Drug combo may have a greater impact on cancer development Cancer researchers have long suggested that new targeted drugs may work best when paired with other therapies. In a new study published today in Cancer Research, scientists have taken some of the first steps to demonstrate this synergy in mouse and cell line models. http://www.news-medical.net/news/2004/09/16/4817.aspx
Bionomics BNO69 angiogenesis gene discovery published Bionomics has announced that research conducted by Bionomics and its collaborators at the Hanson Centre of the Institute of Medical and Veterinary Science ("IMVS") in Adelaide, Australia, relating to Bionomics' proprietary angiogenesis drug target BNO69, has been published in the high ranking scientific journal Proceedings of the National Academy of Sciences USA (PNAS). http://www.news-medical.net/news/2004/08/10/3958.aspx
SU11248 proves effective in the treatment of gastrointestinal stromal tumors A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST). http://www.news-medical.net/news/2004/06/09/2275.aspx
Australian company receives FDA orphan drug designation for product to treat malignant melanomas Progen Industries Limited, an Australian anti-cancer drug development company, announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for their lead anti-angiogenesis product PI-88 for treatment of malignant melanoma. http://www.news-medical.net/news/2004/05/03/1182.aspx
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.